Repligen Co. (NASDAQ:RGEN) Receives $191.50 Consensus Target Price from Brokerages

Repligen Co. (NASDAQ:RGENGet Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $191.50.

Several equities analysts recently issued reports on the company. Stifel Nicolaus dropped their price target on Repligen from $200.00 to $165.00 and set a “buy” rating on the stock in a research report on Wednesday, November 1st. KeyCorp dropped their price target on Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 1st. JPMorgan Chase & Co. boosted their price target on Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 20th. UBS Group dropped their target price on Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a research report on Thursday, November 2nd. Finally, Royal Bank of Canada dropped their target price on Repligen from $207.00 to $200.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 1st.

View Our Latest Analysis on Repligen

Repligen Stock Performance

Repligen stock opened at $193.49 on Friday. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $204.00. The company has a market capitalization of $10.80 billion, a P/E ratio of 95.32, a PEG ratio of 4.50 and a beta of 1.03. The stock has a 50-day simple moving average of $173.86 and a 200-day simple moving average of $163.80.

Repligen (NASDAQ:RGENGet Free Report) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.09. Repligen had a return on equity of 6.08% and a net margin of 17.29%. The business had revenue of $141.20 million during the quarter, compared to the consensus estimate of $140.68 million. During the same period in the previous year, the business earned $0.77 EPS. The business’s quarterly revenue was down 29.6% on a year-over-year basis. As a group, analysts forecast that Repligen will post 1.73 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, insider Christine Gebski sold 3,788 shares of Repligen stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $147.13, for a total value of $557,328.44. Following the completion of the sale, the insider now owns 28,787 shares in the company, valued at approximately $4,235,431.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. Fortis Capital Advisors LLC acquired a new position in shares of Repligen in the 4th quarter valued at about $35,000. Park Place Capital Corp lifted its stake in shares of Repligen by 90.2% in the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 120 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Repligen in the 2nd quarter valued at about $45,000. Signaturefd LLC lifted its position in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in Repligen during the 3rd quarter worth approximately $51,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

(Get Free Report

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.